



Market Announcement

3 April 2024

HeraMED Limited (ASX: HMD) – Trading Halt

Description

The securities of HeraMED Limited ('HMD') will be placed in trading halt at the request of HMD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 5 April 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

ASX ANNOUNCEMENT**3 April 2024**

Lisa Banh
Adviser, Listings
Compliance ASX
Operations
20 Bridge Street
SYDNEY NSW 2000

Via Email: tradinghaltssydney@asx.com.au

Dear Ms Banh

TRADING HALT REQUEST

Medical technology company, **HeraMED Limited (ASX:HMD)** (“HeraMED” or the “Company”) requests that the securities of the Company be placed into a trading halt of up to two trading days with immediate effect.

For the purposes of ASX Listing Rule 17.1 and in support of its request, the Company advises that:

1. The trading halt is requested pending an announcement in relation to changes in Directors and Management, restructure of the business and associated capital requirements including the Shortfall of the Rights Issue¹ (**Purpose**).
2. The Company requests that the trading halt remains in place until the earlier of the Company releasing an announcement regarding the Purpose or prior to the commencement of trading on Friday, 5 April 2024.
3. The Company is not aware of any reason why the request for the trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Your faithfully

David Hinton
Director

-ENDS-

1. Shortfall relates to the closing of the Rights Issue as announced on 28 February 2024